2023 World Conference on Lung Cancer (Posters)-EP12.01. Prognostic Value of Sequential Liquid Biopsy (LB) after Osimertinib Among Hispanic Patients with Advanced EGFR-Mutant NSCLC

EP12.01. Prognostic Value of Sequential Liquid Biopsy (LB) after Osimertinib Among Hispanic Patients with Advanced EGFR-Mutant NSCLC - PDF(Slides)

Back to course

Pdf Summary

This study aimed to evaluate the prognostic value of sequential liquid biopsy (LB) after Osimertinib treatment in Hispanic patients with advanced EGFR-mutant NSCLC. The researchers collected plasma samples from 64 patients between January 2017 and January 2023 and performed next-generation sequencing (NGS) on tumor tissue. They also collected plasma samples routinely at 8 and 24 weeks after Osimertinib treatment. The mean age of the patients was 66 years, and the majority were women with adenocarcinomas. 56.3% were never smokers, and 37.5% had brain metastases at the time of diagnosis. The study found that cfDNA (circulating free DNA) levels at week 8 and week 24 were associated with poorer outcomes. Patients with cfDNA positivity at week 8 had significantly shorter progression-free survival (PFS) and overall survival (OS) compared to those who were cfDNA negative. The same trend was observed for cfDNA positivity at week 24. Multivariate analysis showed that cfDNA positivity at both time points and lack of overall response to Osimertinib were independent predictors of worse OS. The study concluded that monitoring ctDNA (circulating tumor DNA) during Osimertinib treatment can help identify a subgroup of patients with a poor prognosis. It also suggested that the lack of cfDNA negativization could indicate the need for alternative therapies. This study highlights the potential of liquid biopsies in evaluating treatment response and predicting outcomes in EGFR-mutant NSCLC patients.

Asset Subtitle

Andres Cardona

Meta Tag

Speaker Andres Cardona

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

liquid biopsy

Osimertinib treatment

Hispanic patients

EGFR-mutant NSCLC

plasma samples

next-generation sequencing

cfDNA levels

progression-free survival

overall survival

ctDNA monitoring